Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.49 |
| ▸ | GRM5 | P41594 | 10/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31083662 | 1.00 | GRM1 (0.49) | GRM1GRM5CNR1PDK4CDK9 | |
| SCHEMBL31083597 | 0.85 | SMARCA2 (0.40) | GRM1GRM5CNR1 | |
| SCHEMBL25309328 | 0.85 | SMARCA2 (0.40) | GRM1GRM5CNR1 | |
| SCHEMBL25311684 | 0.82 | GRM1 (0.48) | GRM1GRM5CNR1PDK4JAK1 | |
| SCHEMBL31083549 | 0.82 | GRM1 (0.48) | GRM1GRM5CNR1PDK4JAK1 | |
| SCHEMBL5106249 | 0.81 | CNR1 (0.55) | GRM1GRM5CNR1PDK4JAK1 | |
| SCHEMBL25311741 | 0.80 | CNR1 (0.42) | GRM1GRM5CNR1CDK9CCNT1 | |
| SCHEMBL30499652 | 0.80 | CNR1 (0.42) | GRM1GRM5CNR1CDK9CCNT1 | |
| SCHEMBL15556190 | 0.79 | CNR1 (0.55) | GRM1GRM5CNR1PDK4CDK9 | |
| SCHEMBL31342210 | 0.79 | CNR1 (0.55) | GRM1GRM5CNR1PDK4CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100997-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-03-27 | — | — | US | disclosed |
| EP-4463448-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023135107-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023135107-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100997-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | GRM1 1230/4885GRM5 104/4885CNR1 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.